JS
Therapeutic Areas
Thetis Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TP-317 | Ulcerative Colitis (Inflammatory Bowel Disease) | Phase 1b |
Leadership Team at Thetis Pharmaceuticals
GM
Gary Mathias
Co-Founder and CEO
JP
John Parkinson, PhD
Chief Science Officer
BP
Beverly Paperiello
SVP, Development Operations